logo
Cognitive Impact From Dementia Risk Factors Greater in Women

Cognitive Impact From Dementia Risk Factors Greater in Women

Medscape4 hours ago
TORONTO — A number of modifiable risk factors are more common in women than in men and have a greater impact on cognition, an early look at new research showed.
Six modifiable dementia risk factors were more prevalent in women, whereas only three were more common in men. Investigators also found that the impact on cognition from some of these factors was greater in women than in men, especially hearing loss and diabetes.
However, the impact of these and other risk factors varied by age.
Megan Fitzhugh, PhD
The results suggest personalized health and lifestyle interventions should consider both sex and age, study author Megan Fitzhugh, PhD, assistant professor, Department of Neurosciences, University of California San Diego, told Medscape Medical News.
'Clinicians should familiarize themselves with the 14 identified modifiable risk factors, and if their patients have these risk factors, consider their sex and age, and try to target the behavior changes accordingly to minimize the impact on cognition and dementia risk,' Fitzhugh said.
The findings were presented on July 28 at the Alzheimer's Association International Conference (AAIC) 2025.
At Greater Risk
It's well-known that women are at greater risk for dementia. The lifetime risk for Alzheimer's disease (AD) is 1 in 5 for women compared with 1 in 10 for men.
Sex-specific factors such as pregnancy and menopause may contribute to this imbalance. But while many researchers tackle this issue from a biological perspective, Fitzhugh focuses on the effects of modifiable risk factors.
She used the 2008 wave of the Health and Retirement study, an ongoing population-based study of a representative sample of American retirees and their spouses who complete questionnaire every 2 years (in 'waves').
After excluding anyone younger than 40 years and those without self-reported risk factor information, the study sample included 17,182 individuals.
Fitzhugh concentrated on items included in the Lancet Report on Dementia Prevention. As reported by Medscape Medical News , 45% of dementia risk factors are potentially modifiable.
Risk factors identified in the Lancet report include less education in early life (contributing 5% to risk); hearing loss (7%), elevated low density lipoprotein (LDL) cholesterol (7%), depression (3%), traumatic brain injury (3%), physical inactivity (2%), diabetes (2%), smoking (2%), hypertension (2%), obesity (1%), and excessive alcohol (1%) in midlife; and social isolation (5%), air pollution (3%), and vision loss (2%) in late life.
Looking at prevalence, investigators found that six of the 14 risk factors were more common in women, including physical inactivity, depression, smoking, poor sleep, less education and poor vision (for example, glaucoma or cataracts).
Only three risk factors were more common in men, including hearing loss, diabetes, and alcohol use.
There was no difference in prevalence between men and women in high BMI, hypertension, and social isolation.
Plotting Cognition
The Health and Retirement Study also gathers data on global cognition (immediate recall, delayed recall, numeracy, etc.) using a 27-item scale.
Fitzhugh separated mean cognitive scores for men and women and for three age groups (middle age: 40-59 years; middle to older age: 60-79 years; and oldest age: 80 years and over), then plotted risk factors in each group.
The graphs she created illustrate the differences in cognitive performance between having and not having a risk factor for each sex.
For example, the diabetes plot shows this risk factor has a much bigger impact on cognition in women.
'The line for men is relatively flat, so their cognition is really the same if they have diabetes or not, but for women, if they have diabetes, cognition is much lower compared to women who don't have diabetes', explained Fitzhugh.
In addition to diabetes, other risk factors that have a greater cognitive impact on women included poor sleep, BMI, hypertension, poor vision, less education, and hearing loss.
Along with high LDL, hearing loss is the largest modifiable risk factor, accounting for 7% of dementia risk, according to the Lancet Commission report. But even though more men have hearing loss across all ages, it appears to be more impactful on women in terms of cognition, said Fitzhugh.
'Maybe we should be targeting women with hearing loss in middle to older age, making sure they get hearing aids,' she said.
Elsewhere in her research, Fitzhugh found women with hearing loss have a greater risk for dementia than men with hearing loss. 'There's something about hearing loss in women that is particularly detrimental.'
The cognitive impact of risk factors also varies by age, investigators found.
Among women, the impact of hearing loss was greatest in middle to older age. Poor sleep only had a significant impact in middle age, which coincides with the menopause transition. And in the oldest age, less education was the only risk factor to have a significant impact on cognition.
In men, only smoking had a greater cognitive impact, but interestingly, only in the older age group.
'The way I think about age in this study is it's telling us when, potentially, we should be targeting these risk factors,' said Fitzhugh.
She recognizes this is 'just a snapshot' in time and said she'd like to 'map out' how risk factors impact cognition over time.
Commenting on the research, Liisa Galea, PhD, Treliving Family Chair in Women's Mental Health, Centre for Addiction and Mental Health, and professor of psychiatry, University of Toronto, Toronto, Ontario, Canada, said that more modifiable factors are associated with cognition in females than males is 'most surprising.'
'Clearly these factors are important for everyone, but we need more targeted messaging to women across the lifespan about the importance of these variables for their brain health,' Galea said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Will DEA Cole Dismantle Marijuana Research Blockade - MMJ Biopharma Will Be His First Test Case
Will DEA Cole Dismantle Marijuana Research Blockade - MMJ Biopharma Will Be His First Test Case

Associated Press

time15 minutes ago

  • Associated Press

Will DEA Cole Dismantle Marijuana Research Blockade - MMJ Biopharma Will Be His First Test Case

Terry Cole's future as DEA Administrator depends on recognizing the difference between cartels trafficking illicit fentanyl and MMJ's BioPharma Cultivation developing FDA sanctioned cannabinoid medicines for neurological diseases. WASHINGTON, DC / ACCESS Newswire / August 5, 2025 / When President Donald Trump nominated Terrance C. 'Terry' Cole to lead the U.S. Drug Enforcement Administration (DEA), it was a clear signal: Cole's primary mission was to dismantle cartels, combat the synthetic opioid crisis, and restore enforcement-first leadership at an agency long mired in political controversy. With a 22-year career at DEA, followed by a successful stint as Virginia's Secretary of Public Safety, Cole embodies the hardened operational mindset of an agency laser-focused on disruption of illicit drug networks. But now, as DEA Administrator, Cole faces a leadership test that law enforcement experience alone cannot solve: Will he continue the agency's institutional stonewalling of legitimate cannabis pharmaceutical research, or will he embrace scientific integrity and public health necessity by facilitating companies like MMJ BioPharma Cultivation in their quest to bring FDA-approved cannabinoid medicines to patients suffering from Huntington's Disease and Multiple Sclerosis? Cole's Resume: Enforcement Rigor, but Regulatory Inertia? Terry Cole's career achievements are unquestionable. He oversaw complex anti-cartel operations in Mexico and Central America, served as DEA's liaison to the National Security Council, and, as Virginia's chief public safety official, led the state to a 44% reduction in overdose deaths in under a year. These are hard data points that speak to Cole's operational success in traditional enforcement. However, the regulatory side of DEA-particularly its Diversion Control Division-remains deeply flawed. The same bureaucratic apparatus that protected the University of Mississippi's research cannabis monopoly for 50 years has now turned to sabotaging private pharmaceutical developers through endless procedural delays. Cole's predecessors enabled this rot. The question is whether his enforcement first philosophy blinds him to the agency's scientific accountability failures. Boise's Resume: A Public Health Mission Obstructed by DEA Old Guard On the other side stands Duane Boise, President & CEO of MMJ International Holdings. A humanitarian entrepreneur with a 30 year track record in healthcare innovation, Boise has achieved milestones that any biotech CEO would envy: FDA Orphan Drug Designation, two active Investigational New Drug (IND) applications, and a DEA-approved Schedule I analytical lab registration. But despite MMJ's regulatory compliance, the DEA has refused to grant a Bulk Manufacturing Registration, effectively halting clinical trials for plant-derived cannabinoid therapies targeting neurological diseases. For over seven years, MMJ's applications have been entangled in a system designed to protect status quo interests, not scientific progress. Cole's Enforcement Mindset Needs a Public Health Reality Check Terry Cole's nomination under Trump was built on a mandate of enforcement and operational disruption. This makes him instinctively cautious-if not resistant-toward cannabis rescheduling debates and broader reform agendas. However, the MMJ BioPharma case is not about recreational legalization or policy rhetoric. It's about pharmaceutical-grade, FDA-regulated medicines for debilitating diseases. Cole's enforcement instincts must now evolve to recognize a critical distinction: The same laser-focused leadership that Cole used to dismantle cartel networks must now be directed inward-toward rooting out the institutional sabotage within the DEA's own licensing apparatus. What Cole Must Do-Now For Cole to succeed as a transformative leader rather than a caretaker of bureaucratic inertia, he must: The Legacy Crossroads Terry Cole's enforcement résumé has earned him the credibility to confront America's most dangerous narcotics traffickers. But his legacy will not be defined by how many cartel leaders he pursues; it will be judged by whether he had the vision to modernize the DEA into an agency that can differentiate between criminal enterprises and scientific innovation. If Cole ignores the compelling evidence presented by MMJ BioPharma-FDA designations, DEA lab registrations, and clinical urgency-he will perpetuate the very regulatory stagnation that has rendered the DEA's cannabis policy a global embarrassment. But if he acts decisively, Terry Cole has the chance to pivot from enforcement hawk to reformer-a leader who finally corrected the agency's war on science. The choice is his. MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey [email protected] 203-231-8583 SOURCE: MMJ International Holdings press release

Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells
Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells

Yahoo

time42 minutes ago

  • Yahoo

Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells

BEACHWOOD, Ohio, Aug. 5, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company advancing scalable human cell models derived from induced pluripotent stem cells (iPSCs), announces the commercial release of TrailBio® Hematopoietic Progenitor Cells. These progenitor cells are derived from a single, well-characterized iPSC line using Trailhead's proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, providing researchers with a consistent, scalable, and ready-to-use tool for hematopoietic research. TrailBio® Hematopoietic Progenitor Cells express key hematopoietic markers including CD34, CD43 and CD90. Functional characterization confirms their ability to form myeloid and erythroid colonies in colony-forming unit (CFU) assays, differentiate into multiple hematopoietic lineages and demonstrate hematopoietic commitment through transcriptomic profiling. Designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio® Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports reproducible results. "TrailBio® Hematopoietic Progenitor Cells strengthen our portfolio by providing researchers with high-quality, human-relevant cellular models," said David Llewellyn, Chief Executive Officer of Trailhead Biosystems. "Their consistency and multipotency enable scientists to advance research in hematopoietic biology and therapeutic development." "These Hematopoietic Progenitor Cells deliver a dependable combination of purity, potency and versatility," said Angelica Gomes Ueltschy, Scientific Director at Trailhead Biosystems. "Their robust marker expression and multilineage differentiation capacity make them well suited for modeling blood disorders and evaluating therapeutic candidates." Cell characterization information and additional data can be found at About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® Hematopoietic Progenitor Cells join a growing portfolio of iPSC-derived human cell types designed to bridge the gap between discovery and clinical translation. Learn more about Trailhead Biosystems, TrailBio® Hematopoietic Progenitor Cells and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

How Do You Measure a Life? In Caffeinated 5-Hour Bursts
How Do You Measure a Life? In Caffeinated 5-Hour Bursts

New York Times

timean hour ago

  • New York Times

How Do You Measure a Life? In Caffeinated 5-Hour Bursts

Energy drinks aren't meant to be enjoyed. This is why, for a long time, the 5-Hour Energy shot was my energy drink of choice. Where others pile on cloying flavors in an effort to hide their fundamental wretchedness — the rancid cotton-candy tang of Red Bull, the notes of crushed pill in Monster Rehab — 5-Hour Energy seems designed to be as bracingly terrible to drink as possible. The company calls it a dietary supplement, not a beverage. It certainly feels like a potion, viscous and medicinal on the tongue if you let it linger. Thankfully it goes down in a single gulp, though it often leaves a burn, not unlike the feeling of accidentally swallowing a spritz of bug spray. The bottle is small and discreet, faintly recalling the chunky curvature of a battery. One unit packs 200mg of caffeine, the equivalent of about two cups of coffee. One of the 'extra strength' varieties (230mg) used to come wrapped in camouflage packaging: tactical gear for everyday war. The logo, my favorite part of the label, depicts the silhouette of a man running so hard that his feet hover off the ground. He is lifted. I wanted to be lifted, too, though really I would have settled for being able to focus. Like every screen-addled person, I've felt my attention scattering, hopping the fence of my self-discipline to roam where it pleases. Sometime around the beginning of college, I started to try to reclaim my powers of concentration. And here was a little red capsule filled with those lost powers! Best of all, this incredible concoction was available in nearly every convenience store — no need to rely on dorm-room pill pushers. That 5-Hour Energy had come under F.D.A. scrutiny was unknown to me at the time. But even if I had known, it wouldn't have stopped me from taking that first swig. '5-Hour Energy is not an energy drink,' the potion's creator once told Forbes, 'it's a focus drink.' Here's how it goes: After the initial burn subsides, there is a spreading warmth. Heat rises from beneath your skin; dormant powers stir. You may feel like Scarlett Johansson's character in 'Lucy,' suddenly able to use 100 percent of your brain, thanks to the experimental nootropic you've been smuggling in a baggie inside your stomach. You may feel like the character in the manga series 'Naruto' who opens forbidden gates within his soul. You may feel really, insanely tweaked. This is called a 'niacin flush,' and it can happen when you take so much of a certain B vitamin that your capillaries dilate. Whoosh! Caffeine delivery blooms into low-grade ecstatic experience; mild self-harm becomes a sort of lite transcendence. Then, at last, the feeling you've been waiting for. Your world narrows and the horizon contracts until there is only your flushed head, floating somewhere above your irrelevant body, confronting the task before you. For me it took some practice to get the timing right. Many of my first doses sent down the attentional blinders at the wrong moment, and I would find myself spending hours doing things like navigating my hometown on Google Street View. I would emerge disoriented, as from a fugue, regretful that I wasted my precious focus on something stupid. Was this what it felt like to 'lock in?' I had imagined focus as a form of power that would open my senses to more of the world's depth. It would allow me to 'bring [my] best self to every moment,' as a recent 5-Hour ad put it. But over time, the drink itself seemed to chip away at my life. Habitual use taught me to view my time on 5-Hour Energy as already spent or squandered in advance. 5-Hour time was a smooth stretch of oblivion. This was not 'energy,' not the expanding, lifting focus I was looking for. This was focus as world-subtraction. Toward the end of my period of heaviest use, I would down half a bottle before taking a nap. Want all of The Times? Subscribe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store